BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 11579295)

  • 1. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
    International Neoral Renal Transplantation Study Group.
    Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
    Internation Neoral Renal Transplantation Study Group
    Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
    Mahalati K; Belitsky P; Sketris I; West K; Panek R
    Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
    Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
    Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
    Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
    Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
    Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
    Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month.
    Morris RG; Russ GR; Cervelli MJ; Juneja R; McDonald SP; Mathew TH
    Ther Drug Monit; 2002 Aug; 24(4):479-86. PubMed ID: 12142630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).
    Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G
    Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S; Vareesangthip K; Ong-ajyooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
    Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
    Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.